Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725069 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3818750 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3814014 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL7870764 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3820824 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3814693 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL536943 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL1260434 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3816327 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL28615636 | 1.00 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.